Key takeaways
- 10,000–15,000 Estimated UK IgAN patients per UK Renal Registry 2023
- 10–12% Share of incident UK ESRD attributable to IgAN — ~1,000–1,200 cases/year
- £40–50M Estimated annual NHS economic burden of IgAN-attributable ESRD
IgA nephropathy affects an estimated 10,000–15,000 UK patients and drives 10–12% of incident UK end-stage renal disease, a burden NICE built into a £40–50M-a-year economic case for the budesonide and sparsentan appraisals.
IgA nephropathy (IgAN) is an immune-mediated glomerulonephritis caused by mesangial deposition of galactose-deficient IgA1, driving progressive proteinuria and declining eGFR. The UK Renal Registry (2023) identifies IgAN as the UK's second most common primary glomerulonephritis after membranous nephropathy, with an estimated 10,000–15,000 UK patients and approximately 500 new diagnoses per year confirmed via kidney biopsy. IgAN accounts for 10–12% of incident UK end-stage renal disease (ESRD) — roughly 1,000–1,200 UK ESRD cases per year. A network of approximately 80 NHS specialist nephrology centres performs the confirmatory biopsies, giving the UK a comparatively high diagnosis rate.
The Renal Association IgAN guideline (2023, aligned with KDIGO 2021) directs optimal ACEi/ARB therapy for 3–6 months before considering novel agents, targeting blood pressure below 130/80mmHg and UPCR below 0.5g/g. Corticosteroid immunosuppression remains controversial following the STOP-IgAN trial's null result in high-risk patients, with SGLT2 inhibition now being explored. Both novel agents have since cleared NICE technology appraisal: targeted-release budesonide under TA937 (2023, updated by TA1128 in 2026) and sparsentan under TA1074 (June 2025), following MHRA approval of sparsentan in April 2025 — moving IgAN novel-agent access from Named Patient Programme into mainstream NHS commissioning.
UK IgAN treatment landscape — NICE-recommended novel agents against the ACEi/ARB-optimised standard of care
| Drug | Class | Company | MHRA/NICE Status | Key Evidence |
|---|---|---|---|---|
| Tarpeyo (targeted-release budesonide) | Oral targeted glucocorticoid | Calliditas / AstraZeneca | MHRA approved 2023; NICE TA937 (2023), updated by TA1128 (Feb 2026), recommends for NHS funding with a patient access scheme | NefIgArd trial: eGFR slope benefit |
| Filspari (sparsentan) | Dual endothelin/angiotensin receptor antagonist | Travere Therapeutics / CSL Vifor | MHRA approved April 2025; NICE TA1074 (June 2025) recommends for NHS funding — first DEARA approved in this indication | PROTECT trial: UPCR −49.8% |
Sources: UK Renal Registry 2023 annual report; Renal Association IgAN guideline 2023; NICE TA937/TA1128 (budesonide) and TA1074 (sparsentan); NHS PbR tariff 2023–24.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- What is the size of the UK IgAN population eligible for novel agents once ACEi/ARB optimisation has failed to meet Renal Association guideline targets? • UK Renal Registry population sizing • ACEi/ARB-optimised vs novel-agent-eligible segmentation • biopsy-confirmed diagnosis rate by NHS nephrology centre
- What is the NHS economic case for novel IgAN agents, and how does ESRD cost offset factor into the NICE cost-effectiveness model? • NHS renal replacement therapy tariff data (haemodialysis, peritoneal dialysis, transplant) • IgAN-attributable ESRD cost burden • NICE cost-effectiveness framing for eGFR-slope-benefit agents
- How do the budesonide (TA937/TA1128) and sparsentan (TA1074) NICE recommendations compare, and what NHS funding obligations do they create? • NefIgArd and PROTECT trial evidence summary • NICE TA937/TA1128 (budesonide) and TA1074 (sparsentan) recommendations and funding timelines • comparative positioning against the ACEi/ARB-optimised standard of care
What's inside
-
1 · Disease Biology & Galactose-Deficient IgA1 Mechanism 4 pp
- How mesangial deposition of galactose-deficient IgA1 drives the progressive proteinuria and eGFR decline that define IgAN
- Why IgAN ranks as the UK's second most common primary glomerulonephritis after membranous nephropathy
-
2 · UK Renal Registry — 10,000–15,000 Patients, 80 Biopsy Centres 5 pp
- How the UK Renal Registry's biopsy-confirmed data puts the UK IgAN population at 10,000-15,000 patients with roughly 500 new diagnoses a year
- Why the network of roughly 80 NHS specialist nephrology centres performing confirmatory biopsies gives the UK a comparatively high diagnosis rate
-
3 · ACEi/ARB Optimisation — the NHS Standard of Care Before Novel Agents 4 pp
- How the Renal Association's 2023 guideline, aligned with KDIGO 2021, mandates 3-6 months of ACEi/ARB optimisation targeting UPCR below 0.5g/g
- Why corticosteroid immunosuppression remains controversial after STOP-IgAN's null result, pushing focus toward SGLT2 inhibition
-
4 · ESRD Burden — 10–12% of Incident UK ESRD, £40–50M a Year 5 pp
- Why IgAN accounts for 10-12% of incident UK end-stage renal disease, roughly 1,000-1,200 cases a year
- How this translates into an estimated £40-50 million annual NHS economic burden from IgAN-attributable ESRD
-
5 · Novel Agents — Budesonide (NefIgArd) and Sparsentan (PROTECT) 4 pp
- NefIgArd's eGFR-slope benefit for targeted-release budesonide versus PROTECT's -49.8% UPCR reduction for sparsentan, the first DEARA in this indication
- How these two mechanistically distinct novel agents both build their case on delaying progression rather than reversing existing damage
-
6 · NICE Access — From Named Patient Programme to Mainstream Commissioning 4 pp
- How budesonide's TA937 (2023, updated by TA1128 in 2026) and sparsentan's TA1074 (June 2025) moved IgAN access into mainstream NHS commissioning
- Why sparsentan's April 2025 MHRA approval preceded its NICE TA1074 recommendation by just two months, an unusually fast sequence
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx IgA Nephropathy Disease Landscape is built for commercial, medical affairs, and market access teams that need a rigorous, evidence-based characterisation of the UK IgAN patient population and the NHS economic case for novel agents. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, geography, and epidemiological focus.
- 2. Scoping callAXLRx analyst confirms subpopulation scope, data sources, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
UK IgAN disease landscape is built from UK Renal Registry annual reporting, the Renal Association IgAN guideline (aligned with KDIGO 2021), and NHS Payment by Results (PbR) tariff data underpinning the ESRD cost-offset case for novel agents. The UK Renal Registry's biopsy-confirmed cohort gives IgAN unusually reliable UK epidemiological data relative to most rare kidney diseases.
Key sources: UK Renal Registry 2023 annual report; Renal Association IgAN guideline 2023; KDIGO IgAN 2021 guideline; NHS PbR tariff 2023–24; NICE scope for IgAN technology appraisals 2024. All figures carry source citations and are triangulated across multiple primary sources.
- UK IgAN population and ESRD share verified against UK Renal Registry 2023 annual report
- NHS management pathway verified against Renal Association IgAN guideline 2023 and KDIGO IgAN 2021 guideline
- NHS renal replacement therapy cost data verified against NHS PbR tariff 2023–24
- NICE appraisal scope and timeline verified against NICE scope for IgAN technology appraisals 2024
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only — regulatory databases (FDA, MHRA, SFDA), peer-reviewed journals (NEJM, Blood, JAMA), live payer coverage policy documents, and HTA body publications (NICE, ICER, MOH). No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, including additional payer markets, pipeline agent profiles, or country-specific deep-dives, can be added to any standard assessment. Commission via the intake form to start.